A2a receptor antagonist enters Phase 2b trials
 

Biotie announces start of Phase 2b trial of SYN115 in Parkinson's disease

Turku, Finland, April 7th 2011- Biotie Therapies Corp., a development stage company focused on diseases of the central nervous system, today announced the start of a Phase 2b trial evaluating SYN115 in Parkinson's Disease (PD). Results from the study are expected in the first half of 2013.

SYN115 is an orally bioavailable potent and selective adenosine A2a receptor antagonist. Adenosine A2a inhibition has been shown in preclinical studies to reverse motor deficits and enhance the effect of current PD therapies, e.g. levodopa and dopamine agonists, without inducing troublesome dyskinesia (involuntary movements). In addition, SYN115 also displays activity in preclinical models on non-motor symptoms of PD including depression, cognition and anxiety.
http://www.4-traders.com/BIOTIE-THER...ease-13596616/